Correction: Drug manufacturers and intermediaries are being sued by self-funded payers, including state and local governments, unions, businesses, and pension funds, for their insulin pricing policies. Insurance firms were included as plaintiffs in an earlier version of this story. We’ve updated this version.
In a nationwide case over insulin prices, a large number of plaintiffs are attempting to include a number of dubious businesses established by health corporations. They contend that two levels of middlemen selling prescription drugs are unlawfully raising the cost of the life-saving medications.
In the meantime, CVS Health, one of the largest corporations, reported higher-than-expected profits last week while its CEO expressed dissatisfaction over unjust criticism of the drug middlemen.
The three intermediaries that control access to almost 80% of insured patients in the United States are being sued by a wide range of state and municipal governments, unions, businesses, and pension funds. The three businesses that produce nearly all of the insulin sold in the nation are also being sued.
The lawsuit alleges that the middlemen and the medication manufacturers collaborated to increase the drug’s revenues and pricing, which many diabetics depend on for survival.
The intermediaries who made similar statements were sued by the Federal Trade Commission last year.
OUR WORK IS MADE POSSIBLE BY YOU.
Legislation and lawsuits have been brought against the middlemen and their corporate parents across the United States, claiming that they inflate the prices of a variety of medications in order to increase their profits.
In drug transactions, the intermediaries, often known as pharmacy benefit managers, or PBMs, act on behalf of insurers, including those that are owned by their parent companies. They establish networks of pharmacies, both those they own and others they compete with, and decide how much to pay them back. Independent pharmacies have long claimed that they were forced out of business by the large PBM parent corporations using this convoluted and perhaps conflicting method.
Crucially, the large PBMs also choose which medications receive preferential treatment, frequently in the form of the lowest copayments, and which are covered by insurance. Pharmaceutical companies pay PBMs large, frequently opaque fees and discounts in order to get their drugs listed on formularies and receive preferential treatment because they want their products to be covered.
The complaints allege that Cigna-Express Scripts, United Health Group, and CVS Health excluded less expensive kinds of insulin from their formularies in an effort to increase their payments to pharmaceutical companies. According to the FTC, state and local governments, and self-funded insurers, this has the effect of unjustly raising prices.
The plaintiffs in the multi-district lawsuit, which was launched by the state and local governments as well as other self-funded organizations, are now attempting to sue yet another group of middlemen that the health corporations have established over the last five years.
They are known as group purchasing organizations, and they represent PBMs in rebate negotiations. Critics claim that two of them, which have their headquarters abroad, were established to conceal their operations behind yet another black curtain in the face of heightened industry scrutiny. Additionally, they assert that it’s a means of collecting even more fees and increasing revenue.
Mark Pifko, co-lead counsel in the case, said in a statement that the group purchasing organizations “keep billions in additional fees from manufacturers and (obscure) the payment trail of rebates that rightfully belong to self-funded payers.”
GET THE HEADLINES FOR THE MORNING.
On similar grounds, the FTC has previously filed a lawsuit against the purchasing organizations.
Last week, despite lawsuits from the federal government and all other levels of government, CVS reported a $4.6 billion profit for 2024, exceeding forecasts and causing its stock price to surge.
CEO David Joyner made the unusual move of claiming during the earnings call that his company was being singled out by the litigating government agencies.
According to Fierce Healthcare, PBMs like (CVS) Caremark are among the most potent tools assisting in mitigating the rise in health care expenses, according to Joyner. These organizations are still the only ones in the drug supply chain that are only concerned with cutting costs, yet they have mistakenly been the target of misleading language and false facts.
However, it is impossible to determine if CVS and the other two health conglomerates are contributing to or offsetting growing health care prices because they have refused to make all of their pricing, pharmacy reimbursement, fee, and manufacturer discount data publicly available. Joyner still claimed that others were selectively using certain data.
Therefore, the conclusion is obvious when you examine all the data, not just the data points that are specifically mentioned in the FTC interim reports, he said: PBMs save their clients money. One of the most important ways to guarantee that Americans pay less for medications has been and still is Caremark.
Eliot Pierce is a dedicated writer for ChiefsFocus.com, covering local crime and finance news. With a keen eye for detail and a passion for storytelling, Eliot aims to provide his readers with clear and insightful analysis, helping them navigate the complexities of their financial lives while staying informed about important local events. His commitment to delivering accurate and engaging content makes him a valuable resource for the community.